Humana Inc. (HUM)
NYSE · Louisville, Kentucky, USA · Founded 1961 · CEO Jim Rechtin
Valuation summary
$1,087.50 fair value versus $380.00 in the market, a difference of +186.2%. Rated Strong Buy.
| Fair value per share | $1,087.50 |
| Current share price | $380.00 |
| Upside / downside | +186.2% |
| Bear case | $348.31 |
| Bull case | $2,254.83 |
| Discount rate (WACC) | 9.9% |
| Terminal growth | 2.40% |
| Market capitalisation | $46B |
| EV / Sales | 0.3x |
About Humana Inc.
Founded in 1961 as a nursing home operator, later a hospital company, and health insurance only from the 1980s. Jim Rechtin became CEO in 2024. Humana is the second largest Medicare Advantage insurer, covering older Americans through privately administered Medicare, and operates primary care clinics through CenterWell.
Investment case
- Medicare Advantage enrolment grows structurally with an ageing population.
- CenterWell clinics give it control over care delivery costs, not just insurance risk.
- Deep experience in Medicare specifically, rather than as one line among many.
Key risks
- Medical cost utilisation ran far above pricing assumptions, causing severe margin damage.
- Star ratings declines directly reduce bonus payments, and one downgrade costs hundreds of millions.
- Almost entirely dependent on a single government programme and its reimbursement decisions.
Recent developments
- 2026-10-01 · Humana outlined 2027 Medicare Advantage plans in about 2,600 counties across 45 states, standardising core benefits and expanding chronic-condition special needs plans source
- 2026-09-25 · Barclays upgraded Humana to Overweight and raised its target to $515 from $407; shares rose about 7% to $406, up about 60% year to date source
- 2026-09-10 · CMS draft 2027 star cutpoints were tougher on about half of measures; Humana says it expects stars to be meaningfully higher next year source
- 2026-08-14 · Humana is exiting plans covering about 600,000 Medicare Advantage members for 2027, roughly 8% of its 7.2 million MA members, as disclosed on its Q2 call source
Revenue by segment
| Medicare Advantage | 78% |
| Group & Specialty | 12% |
| CenterWell Services | 10% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $185.5B | $4.9B |
| Year 2 | $220.5B | $6.3B |
| Year 3 | $255.2B | $7.7B |
| Year 4 | $287.2B | $9.2B |
| Year 5 | $314.1B | $10.6B |
What the street says
Sentiment has turned more constructive: Barclays upgraded the shares to Overweight on 25 September 2026 with a $515 target, and the stock was up about 60% this year. The debate now centres on whether 2027 star ratings recover after only about 20% of members sat in four-star-plus plans for 2026, with draft cutpoints for 2027 tougher on about half of measures.
Comparable companies: CAH · MDLN · CNC · COR · DXCM · NTRA · MCK · CI
Open the interactive model, price chart and sensitivity grid →